Skip to main content
SpringerLink
Log in

Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice

  • Chapter
  • First Online:
Tumor Models in Cancer Research

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

As preclinical chemotherapists, we are often asked to identify experimental tumor models that can accurately predict for the drug response characteristics of all tumors of a given cellular subtype or molecular target. Unfortunately, it is impossible to give satisfactory answers to these inquiries. Because of the unique character of each independently arising tumor (whether spontaneous or induced), it does not take very long to realize that each tumor is a unique biologic entity with its own tumor growth behavior, histological appearance, drug response and molecular expression profiles. This is true whether the tumor is an experimental animal model or one originally derived from a patient. Further, many factors can influence the tumor growth and therapy response of experimental tumor models. Still, in vivo models are needed to adequately assess pharmacodynamics, toxicity and efficacy of any potential novel therapy. Presented herein is what we hope will be useful information regarding the transplant characteristics of tumor models, with some of the “pitfalls” to look out for when using any given tumor model for chemotherapy evaluations. Although most of the examples given use syngeneic models, the methodologies for assessing the predictive worth and maintaining model usefulness can be applied to almost any given transplantable tumor system (whether syngeneic or xenograft).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    There is a relationship between tumor size and cell number. With syngeneic, transplanted mouse tumors, the tumor mass is usually >85% tumor cells while in exponential growth. A 1 g mass (1,000 mg) = 1 × 109 cells; a 0.1 g mass (100 mg) = 1 × 108 cells; a 0.01 g mass (10 mg) = 1 × 107 cells; a 1 mg mass = 1 × 106 cells, and so on. Thus, a 30 mg mass = 3 × 107 cells (30 million cells). Human tumor cells and mouse tumor cells are approximately the same size, but only a few xenografted human tumors contain >80% tumor cells. Td = exponential tumor-volume doubling time. 3.32 = number of doublings per log. Cure is usually obtained when the population is reduced to approximately 10 or 100 cells for most solid tumors.

References

  1. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacogn. 1995;33(Suppl.):102–22.

    Article  CAS  Google Scholar 

  2. LoRusso P, Demchik L, Dan M, Polin L, Gross JL, Corbett TH. Comparative efficacy of DMP840 against mouse and human solid tumor models. Invest New Drugs. 1995;13:195–203.

    Article  PubMed  CAS  Google Scholar 

  3. Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, et al. Treatment of human prostate tumors PC-3 and TSU-PRI with standard and investigational agents in SCID mice. Invest New Drugs. 1997;15:99–108.

    Article  PubMed  CAS  Google Scholar 

  4. Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep. 1978;62(10):1471–88.

    PubMed  CAS  Google Scholar 

  5. Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434–9.

    PubMed  CAS  Google Scholar 

  6. Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 1977;40(5):2660–80.

    Article  PubMed  CAS  Google Scholar 

  7. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717–26.

    PubMed  CAS  Google Scholar 

  8. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman RF, editor. The use of rodent tumors in experimental cancer therapy: conclusions and recommendations. New York, NY: Pergamon; 1987. p. 233–47.

    Google Scholar 

  9. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, et al. In vivo methods for screening and preclinical testing; use of rodent solid tumors for drug discovery. In: Teicher B, editor. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa, NJ: Humana Press Inc.; 1997. p. 75–99.

    Google Scholar 

  10. Corbett TH, Griswold DP, Jr, Roberts BJ, Schabel FM, Jr. Cytotoxic adjuvant therapy and the experimental model. In: Stoll BA, editor. New aspects of breast cancer. Vol. 4, Systemic therapy in breast cancer. London: William Heinemann Medical Books; 1981. p. 204–43.

    Google Scholar 

  11. Corbett TH, Roberts BJ, Lawson AJ, Leopold WR, III. Curative chemotherapy of advanced and disseminated solid tumors of mice. In: Jacobs JR, Al-Sarraf M, Crissman J, Valeriote F, editors. Scientific and clinical perspectives in head and neck cancer management: strategies for cure. New York, NY: Elsevier Scientific; 1987. p. 175–92.

    Google Scholar 

  12. Griswold DP, Jr, Corbett TH. Use of experimental models in the study of approaches to treatment of colorectal cancer. In: Lipkin M, Good RA, editors. Gastrointestinal tract cancer. New York, NY: Medical Book; 1978. p. 399–418.

    Google Scholar 

  13. Karrer K, Humphreys SR. Continuous and limited courses of cyclophosphamide (NSC26271) in mice with pulmonary metastasis after surgery. Cancer Chemother Rep. 1967;51:439–49.

    Google Scholar 

  14. Schabel FM Jr. Concepts for treatment of micrometastases developed in murine systems. Am J Roentgenol Radium Ther Nucl Med. 1976;126:500–11.

    Google Scholar 

  15. Boyd MR. The NCI in vitro anticancer drug discover screen, concept, implementation, and operation, 1985 to 1995. In: Teicher B, editor. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa, NJ: Humana; 1997. p. 75–99.

    Google Scholar 

  16. Wallace AC. Effect of delayed addition of irradiated cells to small viable tumor inocula. Cancer Res. 1965;25:355–7.

    PubMed  CAS  Google Scholar 

  17. Revesz L. Effect of tumor cells killed by X-rays upon growth of admixed viable cells. Nature. 1956;178:1391–2.

    Article  PubMed  CAS  Google Scholar 

  18. Revesz L. Effect of lethally damaged tumor cells upon the development of admixed viable cells. J Natl Cancer Inst. 1958;20:1157–86.

    PubMed  CAS  Google Scholar 

  19. Dykes DJ, Griswold DP, Jr, Schabel FM, Jr. Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor. Cancer Res. 1978;36:2031–4.

    Google Scholar 

  20. Annual Progress Report to Division of Cancer Treatment, National Cancer Institute on Primary Screening and Development and Application of Secondary Evaluation Procedures for Study of New Materials with Potential Anticancer Activity. Lack of Influence of immune suppression on the number of cells required to establish takes of solid tumors. Southern Research Institute, Contract NO1-CM-43756, March 15, 1982. p. 1–9.

    Google Scholar 

  21. Skipper HE. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res. 1965;25:1544–50.

    PubMed  CAS  Google Scholar 

  22. Laster WR, Jr, Schabel FM, Jr, Skipper HE, Wilcox WS, Thomson JR. Experimental evaluation of potential anticancer agents IV. Host weight loss as it related to false positives in drug evaluation. Cancer Res. 1961;21:895–906.

    PubMed  CAS  Google Scholar 

  23. Annual Progress Report to Division of Cancer Treatment, National Cancer Institute on Primary Screening and Development and Application of Secondary Evaluation Procedures for Study of New Materials with Potential Anticancer Activity. Section 27. Unusual toxicity problems encountered in the evaluation of new antitumor agents: implications for data analysis and protocol design. Southern Research Institute, Contract NO1-CM-43756, March 15, 1982. p. 1–32.

    Google Scholar 

  24. Houghton JA, Taylor DM. Growth characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br J Cancer. 1978;37:213–23.

    Article  PubMed  CAS  Google Scholar 

  25. LoRusso PM, Polin L, Aukerman SL, Redman BG, Valdivieso M, Biernat L, et al. Antitumor efficacy of Interleukin-2 alone and in combination with Adriamycin and Dacarbazine in murine solid tumor systems. Cancer Res. 1990;50:5876–82.

    PubMed  CAS  Google Scholar 

  26. Motycka K, Bostik J, Danek PF, Chudomel V. Immunogenicity of the Gardner lymphosarcoma for the mice of the strain C3H (H-2k). I. The effect of the 60Co-irradiation of recipients and of the interval between the immunization and transplantation of the tumor on the antitumor resistance of immunized mice. Neoplasma 1986;33(2):167–75.

    PubMed  CAS  Google Scholar 

  27. Simpson-Herren L, Corbett TH, Griswold DP, Jr. The cell population kinetics and response to an S-phase specific agent of three transplantable colon tumor lines. Cell Tissue Kinet. 1980;13:613–24.

    PubMed  CAS  Google Scholar 

  28. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP, Jr, Schabel FM, Jr. Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res. 1982;42:1707–15.

    PubMed  CAS  Google Scholar 

  29. Corbett TH, Roberts BJ, Trader MW, Laster WR, Jr, Griswold DP, Jr, Schabel FM, Jr. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep. 1982;66(5):1187–200.

    PubMed  CAS  Google Scholar 

  30. Corbett T, Valeriote F, Baker L. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs. 1987;5:3–20.

    Article  PubMed  CAS  Google Scholar 

  31. Corbett TH, Bissery M-C, LoRusso P-M, Polin L. 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 1989;7:37–49.

    Article  PubMed  CAS  Google Scholar 

  32. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, et al. Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol. 1996;1:95–108.

    PubMed  CAS  Google Scholar 

  33. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, et al. Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs. 1997;15:207–18.

    Article  PubMed  CAS  Google Scholar 

  34. Corbett TH, LoRusso P, Demchick L, Simpson C, Pugh S, White K, et al. Preclinical antitumor efficacy of analogs of XK-469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy] propionate. Invest New Drugs. 1998;16:129–39.

    Article  PubMed  CAS  Google Scholar 

  35. Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K, et al. Preclinical Efficacy of thioxanthone SR-271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs. 1999;17:17–27.

    Article  PubMed  CAS  Google Scholar 

  36. Schabel FM, Jr, Trader MW, Jr, Laster WR, Jr, Corbett TH, Jr, Griswold DP, Jr. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979;63:1459–73.

    PubMed  CAS  Google Scholar 

  37. Schabel FM, Jr, Skipper HE, Trader MW, Laster WR, Jr, Griswold DP, Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983;67:905–22.

    PubMed  Google Scholar 

  38. Skipper HE, Schabel FM, Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetic associated with curability of experimental leukemias. Cancer Chemother Rep. 1964;35:3–111.

    Google Scholar 

  39. Kessel D, Corbett TH. Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of mice. Cancer Lett. 1985;28:187–93.

    Article  PubMed  CAS  Google Scholar 

  40. Biernat L, Polin L, Corbett T. Adaptation of mammary tumors of mice to a soft agar assay for use in drug discovery. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract #185, Amsterdam, March 1992. p. 17–20.

    Google Scholar 

  41. Smith WE, Yazdi E, Miller L. Carcinogenesis in pulmonary epithelia in mice on different levels of Vitamin A. Environ Res. 1972;5:152–63.

    Article  PubMed  CAS  Google Scholar 

  42. Tapazoglou E, Polin L, Corbett TH, Al-Sarraf M. Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations. Invest New Drugs. 1988;6(4):259–64.

    Article  PubMed  CAS  Google Scholar 

  43. Sugiura K, Stock CC. Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors. Cancer Res. 1955;15:38–51.

    PubMed  CAS  Google Scholar 

  44. Law LW, Dunn TB, Boyle PJ, Miller JH. Observations on the effect of folic-acid antagonists on transplantable lymphoid leukemias in mice J Natl Cancer Inst. 1949;10:179–92.

    PubMed  CAS  Google Scholar 

  45. Dawe CJ, Potter M. Morphologic and biologic progression of a lymphoid neoplasm of the mouse in vivo and in vitro (abstr). Am J Pathol. 1957;33:603.

    Google Scholar 

  46. Bradner WT, Pindell MH. Myeoid leukemia C1498 as a screen for cancer chemotherapeutic agents Cancer Res. 1966;April(pt 2):375–90.

    Google Scholar 

Download references

Acknowledgments

This work was supported by CA12623, CA82341, CA53001, Sanofi-Aventis previously Sanofi Synthelabo Research, and Eli Lilly Corporation.

Author information

Authors and Affiliations

  1. Solid Tumor Drug Discovery Lab, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Prentis Building, Room 2232, 110 E. Warren Avenue, Detroit, MI, 48201, USA

    Lisa Polin

Authors
  1. Lisa Polin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas H. Corbett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bill J. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alfred J. Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wilbur R. Leopold III
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kathryn White
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juiwanna Kushner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stuart Hazeldine
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Richard Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. James Rake
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jerome P. Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Polin .

Editor information

Editors and Affiliations

  1. Genzyme Corporation, Mountain Rd. 1, Boston, 01701, Massachusetts, USA

    Beverly A. Teicher

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Polin, L. et al. (2011). Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice. In: Teicher, B. (eds) Tumor Models in Cancer Research. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-968-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-968-0_3

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-967-3

  • Online ISBN: 978-1-60761-968-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation